AZ's Fasenra Gets Boost From Steroid-Sparing Data
Expansion Plans For Big-Selling Biologic
The POTENTE trial demonstrated Fasenra’s impact in eliminating or reducing oral corticosteroid use for severe asthma patients, which should help AstraZeneca as it takes on GlaxoSmithKline’s rival IL-5 inhibitor, Nucala.
You may also be interested in...
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.